Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2010-08-12
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 95
- Registration Number
- NCT00143975
- Locations
- 🇦🇹
St. Johann Hospital, Clinical Center of Salzburg, Salzburg, Austria
🇩🇪Department of Hematology, Hemostaseology and Oncology, Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Medical Department II, City Hospital Karlsruhe gGmbH, Karlsruhe, Germany
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 481
- Registration Number
- NCT00137995
- Locations
- 🇮🇱
Israel Society of Hematology, Tel-Hashomer, Israel
🇨🇭Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇫🇮Hospital district of south west Finland, Turku, Finland
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT00136435
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇨🇦Manitoba Blood & Marrow Transplant Program CancerCare Manitoba, Winnipeg, Manitoba, Canada
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2018-09-17
- Target Recruit Count
- 23
- Registration Number
- NCT00133991
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 120
- Registration Number
- NCT00131053
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 240
- Registration Number
- NCT00131027
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 100
- Registration Number
- NCT00130195
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Kanisa Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT00129168
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
- First Posted Date
- 2005-08-03
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00126191
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2013-05-03
- Target Recruit Count
- 30
- Registration Number
- NCT00124644
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.